Neu J, Ariagno R L, Johnson J D, Pitlick P T, Cohen R S, Beets C L, Sunshine P
Pediatr Pharmacol (New York). 1981;1(3):245-9.
Over a two year period, 52 infants were found to have clinical signs of patent ductus arteriosus (PDA). Twenty-seven responded to fluid restriction and furosemide; the remaining 25 infants entered the Indomethacin (IN) study protocol. Their mean (+/- SE) gestational age was 29.3 (+/- 0.6) weeks and birth weight was 1,142 (+/- 80) gm. Either a placebo or IN (0.25 mg/kg) orally was given for two doses, 24 hours apart; if no response occurred, the patient was crossed over to the opposite medication. Using Chi-square analysis, a significant response rate to IN was found. There were no significant differences in birth weights, gestational ages, or fluid intake between responders and nonresponders. However, both responders and nonresponders required a prolonged ventilator course, suggesting factors other than PDA causing prolonged ventilatory requirements in these babies.
在两年的时间里，发现52例婴儿有动脉导管未闭（PDA）的临床症状。27例对液体限制和速尿有反应；其余25例婴儿进入吲哚美辛（IN）研究方案。他们的平均（±标准误）胎龄为29.3（±0.6）周，出生体重为1142（±80）克。口服安慰剂或IN（0.25mg/kg），分两剂，间隔24小时；如果没有反应，患者改用另一种药物。使用卡方分析，发现对IN有显著反应率。反应者和无反应者之间的出生体重、胎龄或液体摄入量没有显著差异。然而，反应者和无反应者都需要延长呼吸机使用时间，这表明除PDA外的其他因素导致这些婴儿需要延长通气时间。
